Posted by Michael Wonder on 16 Jul 2018
PhRMA responds to Trump blueprint with its own drug-pricing proposal: reduce payments to PBMs
16 July 2018 -The drug manufacturing industry’s main lobbying group is backing a big change to the way prescription drugs are priced, but it’s unclear how it would impact the industry’s business model.
It looks like PhRMA is embracing one of the Trump administration’s biggest ideas for addressing prescription drug prices — eliminating rebates that drug makers pay to pharmacy benefit managers, the middlemen that negotiate drug prices on behalf of insurance companies.
But the plan doesn’t spell out what it will do and whether it will bring down the price of drugs for patients.
